Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

IntroductionSPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety an...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Frontiers Media S.A. 2025-01-01
Cyfres:Frontiers in Oncology
Pynciau:
castration resistant prostate cancer
PSMA
radioligand therapy
PNT2002
dosimetry
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fonc.2024.1483953/full

Rhyngrwyd

https://www.frontiersin.org/articles/10.3389/fonc.2024.1483953/full

Eitemau Tebyg